Bridge Therapeutics, a late development-stage specialty pharmaceutical company, has added Steven Passik PhD to its Scientific Advisory Board, it was reported yesterday.
Dr Passik PhD, Clinical Psychology, is a leader and researcher in pain management and addiction. He has written extensively on the treatment of cancer and AIDS patient's pain management. He has been a principal investigator for numerous clinical trials funded by both pharmaceutical companies and government funded organisations. He has been the recipient of numerous awards for his excellence in clinical research.
Dr Greg Sullivan, chief science officer and founder of Bridge Therapeutics said, 'Dr Passik has a wealth of knowledge on the practical application of pain management in the real world, not just in the clinical setting. I'm excited to see what he will add to Bridge's efforts in developing safer chronic pain treatments.'
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results